Radiation Nephropathy Treatment and Management Demand Fuelled by Growing Awareness and Initiatives for kidney diseases Management, Says Fact.MR
04 Mar 2021
Fact.MR, a global research & consulting firm, in their updated edition of the report, indicated that the radiation nephropathy treatment and management market is slated to record a sturdy growth pace in 2021 and beyond. Growing number of patients experiencing diabetes and cholesterol are also projected to generate higher demand of radiation nephropathy treatment & management. Additionally, combined prevalence of key renal ailments such as, focal segmental glomerulosclerosis, atherosclerosis, and renal artery stenosis is furthermore one of the prime aspects driving the industry’s growth.
“Surge in clinical trial for drug development together with the support of government organization is anticipated to bolster the expansion of radiation nephropathy treatment & management industry.” states Fact.MR.
Rising Prevalence for Kidney Disorders will Encourage Industry Growth
The radiation nephropathy treatment & management industry is primarily fuelled by growing prevalence of kidney disorders and growing patient population experiencing renovascular hypertension. In U.S. about, 661,000 American have kidney failure in 2013 and over 47,000 Americans died from kidney ailment.
Additionally, government initiatives to boost awareness regarding early radiation nephropathy treatment & management, will be fuelling the the industry. For example, public and private healthcare organization is progressively taking initiatives for management of kidney diseases which will encourage the industry growth.
Request a report sample to gain comprehensive market insights at
ACE Inhibitor to Remain Lucrative
Angiotensin-converting enzyme (ACE) inhibitor is projected to contribute huge revenue share in radiation nephropathy treatment and management industry. These drugs also enhance the survival rate of individuals who have lasted heart attacks as well as they avert early death of individuals from diverse ailments. Oftentimes ACE inhibitors are joined with other drugs for treating a condition.
Furthermore with ACE inhibitor, diuretic drugs and angiotensin II receptor blockers are also prescribed to control the renal hyper.
How huge is the Opportunity will be in the US?
The US and the UK are anticipated to be the lucrative regions in the radiation nephropathy treatment and management industry due to huge patient pool.
China, India and South Korea is likely to expand at a higher CAGR as a result of the growing healthcare expenditure as well as increasing healthcare facilities.
Get Customization on this Report for Specific Research Solution
Development of Novel Radiation Nephropathy Management & Treatment Drugs Remain Key Focus Area: Fact.MR Survey
The radiation nephropathy treatment and management market appears to be greatly fragmented in nature with the existence of several manufacturers. Fact.MR’s survey indicated that the key market players are focusing on conducting clinical trials for the expansion of novel radiation nephropathy management and treatment drugs. The updated edition of the report offers comprehensive coverage of the projected remain key strategies of the market players. Some of the major market players profiled in the report are Par Pharmaceutical Companies, Inc., Silvergate Pharmaceuticals, Inc., Pfizer Inc., Merck & Company, Inc., Novartis AG, AstraZeneca plc., Johnson and Johnson, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Bayer AG, Sanofi SA, ALEMBIC PHARMS LTD, Teva Pharmaceutical Industries Ltd. and Daiichi Sankyo GlaxoSmithKline plc. The latest edition also provides a thorough analysis of the COVID-19 impact on this market.
Explore Fact.MR’s Healthcare Reports
Th17 Driven Disease Treatment Market: Delve into Fact.MR’s extensive study on the Th17 driven disease treatment market, offering detailed assessment. The study analyses crucial trends that are currently determining, and those which are expected to shape future expansion trajectory, shedding light on the vital dynamics such as drivers, restraints and opportunities.
Closed Blood Sampling Systems Market: The global rapid oral fluid screening devices market study published by fact.mr incorporates detailed assessment of the market landscape, taking into consideration value chain analysis, business execution and supply chain analysis across key markets.
PDA Closure Devices Market: Fact.MR’s global peptide based metabolic disorders therapeutics market research report provides stakeholders with an exhaustive analysis on key market dynamics, such as the drivers, restraints, opportunities and trends responsible for shaping the future expansion trajectory.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Organizations
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.